Adolor 8-K 2005
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) November 16, 2005
(Exact name of registrant as specified in its charter)
Registrants telephone number, including area code: (484) 595-1500
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Item 1.01 Entry into a Material Definitive Agreement.
Adolor Corporation, a Delaware corporation (the Company), and Corium International, Inc., a Delaware corporation (Corium) entered into a Scale Up and Commercial Supply Agreement effective November 16, 2005 (the Agreement). Under the terms of the Agreement, Corium will engage in a development program to develop and scale up production of a prescription-only, passive, sterile lidocaine patch (the Patch) for human use for pain from closed wounds. The Company will make payments to Corium in exchange for Coriums performance of its development obligations as outlined in the Agreement. Under the terms of the Agreement, Corium will manufacture clinical supplies of the Patch as ordered by the Company. Under the Agreement, Corium will scale up the production of the Patch. Under the Agreement Corium will be the exclusive supplier of Patches to the Company commencing with the Effective Date and continuing for a period of time agreed by the parties. The Agreement covers ordering terms and provides for commercial supply terms when and if the Patch is approved for commercial sale by the Food and Drug Administration.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
Dated: November 22, 2005